Lumida
/EBS
⌘K
Emergent BioSolutions Inc

Emergent BioSolutions Inc

EBS
$7.63USD-0.78%-0.06 today

MARKET CAP

393.7M

P/E (TTM)

7.6x

FWD P/E

8.0x

DAY RANGE

$7 – $8

52W RANGE

$6
$14

AI Summary

Stalk
TrimMedium

The stock is entrenched in a Stage 4 decline, trading sideways below its major moving averages with persistent lower highs and lower lows. Medium-term bias remains bearish, permitting only sell-side engagement, while short-term conditions lack a clear timing edge. Execution is deferred until price rallies into resistance around the 9/21 EMA cluster or the upper consolidation boundary, where rejection at EMAs can be probed for trade entries.

  • Q4’25 revenue $743M and adj. EBITDA $205M (+12% YoY)
  • Secured $52.7M government contracts; international sales 34% of MCM revenue
  • 2026 lacks repeat of $60M intl order, exposing contract volatility
Full analysis →
Insider Trades59 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 1, 2026SellEBSPaul Anthony WilliamsSVP, Products Business3,000$8.40$393.7M-45.73%+35.89%$25.2K-1.85%Trim
Jun 8, 2026SellEBSPaul Anthony WilliamsSVP, Products Business694$8.00$393.7M-45.73%+35.89%$5.6K-0.43%Trim
Jun 8, 2026SellEBSWilliam HartzelSVP, Bioservices1,741$8.00$393.7M-45.73%+35.89%$13.9K-0.93%Trim
Jun 8, 2026SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL2,018$8.00$393.7M-45.73%+35.89%$16.1K-0.99%Trim
Jun 8, 2026SellEBSRichard S LindahlEVP, Chief Financial Officer3,964$8.00$393.7M-45.73%+35.89%$31.7K-1.05%Trim
Apr 1, 2026SellEBSPaul Anthony WilliamsSVP, Products Business4,000$8.44$393.7M-45.73%+35.89%$33.8K-6.00%Trim
Mar 5, 2026SellEBSJessica PerlSVP, General Counsel, Corp Sec6,465$8.44$393.7M-45.73%+35.89%$54.6K-3.08%Trim
Mar 5, 2026SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL8,199$8.44$393.7M-45.73%+35.89%$69.2K-2.02%Trim
Mar 5, 2026SellEBSPaul Anthony WilliamsSVP, Products Business9,397$8.44$393.7M-45.73%+35.89%$79.3K-2.84%Trim
Mar 5, 2026SellEBSWilliam HartzelSVP, Bioservices9,493$8.44$393.7M-45.73%+35.89%$80.1K-2.66%Trim
Mar 5, 2026SellEBSSimon C LowrySVP, R&D, CMO10,636$8.44$393.7M-45.73%+35.89%$89.8K-4.50%Trim
Mar 5, 2026SellEBSRichard S LindahlEVP, Chief Financial Officer23,650$8.44$393.7M-45.73%+35.89%$199.6K-2.97%Trim
Mar 5, 2026SellEBSJoseph C PapaPresident and CEO37,055$8.44$393.7M-45.73%+35.89%$312.7K-1.74%Trim
Mar 1, 2026SellEBSPaul Anthony WilliamsSVP, Products Business116$8.15$393.7M-45.73%+35.89%$945.4-0.15%Trim
Mar 1, 2026SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL313$8.15$393.7M-45.73%+35.89%$2.6K-0.28%Trim
Mar 1, 2026SellEBSRichard S LindahlEVP, Chief Financial Officer683$8.15$393.7M-45.73%+35.89%$5.6K-0.28%Trim
Feb 9, 2026SellEBSJessica PerlSVP, General Counsel, Corp Sec918$11.03$393.7M-45.73%+35.89%$10.1K-1.34%Trim
Feb 6, 2026SellEBSWilliam HartzelSVP, Bioservices630$10.92$393.7M-45.73%+35.89%$6.9K-0.65%Trim
Feb 6, 2026SellEBSPaul Anthony WilliamsSVP, Products Business1,022$10.92$393.7M-45.73%+35.89%$11.2K-1.32%Trim
Feb 6, 2026SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL2,852$10.92$393.7M-45.73%+35.89%$31.1K-2.47%Trim
Feb 6, 2026SellEBSRichard S LindahlEVP, Chief Financial Officer5,642$10.92$393.7M-45.73%+35.89%$61.6K-2.30%Trim
Dec 14, 2025SellEBSSimon C LowrySVP, R&D, CMO3,543$11.41$393.7M-45.73%+35.89%$40.4K-3.85%Trim
Nov 11, 2025SellEBSWilliam HartzelSVP, Bioservices610$10.88$393.7M-45.73%+35.89%$6.6K-0.59%Trim
Oct 15, 2025SellEBSRichard S LindahlEVP, Chief Financial Officer4,995$9.60$393.7M-45.73%+35.89%$48.0K-1.68%Trim
Oct 7, 2025SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL30,608$10.00$393.7M-45.73%+35.89%$306.1K-17.50%Trim
Jul 11, 2025SellEBSWilliam HartzelSVP, Bioservices4,263$7.36$393.7M-45.73%+35.89%$31.4K-3.95%Trim
Jun 8, 2025SellEBSPaul Anthony WilliamsSVP, Products Business464$6.63$393.7M-45.73%+35.89%$3.1K-0.54%Trim
Jun 8, 2025SellEBSWilliam HartzelSVP, Bioservices1,167$6.63$393.7M-45.73%+35.89%$7.7K-1.07%Trim
Jun 8, 2025SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL1,249$6.63$393.7M-45.73%+35.89%$8.3K-0.71%Trim
Jun 8, 2025SellEBSRichard S LindahlEVP, Chief Financial Officer2,733$6.63$393.7M-45.73%+35.89%$18.1K-0.91%Trim
May 13, 2025BuyEBSJoseph C PapaPresident and CEO60,000$5.83$393.7M-45.73%+35.89%$349.8K+21.24%Trim
Apr 7, 2025SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL480$4.44$393.7M-45.73%+35.89%$2.1K-0.27%Trim
Apr 7, 2025SellEBSWilliam HartzelSVP, Bioservices561$4.44$393.7M-45.73%+35.89%$2.5K-0.51%Trim
Mar 5, 2025SellEBSWilliam HartzelSVP, Bioservices292$5.80$393.7M-45.73%+35.89%$1.7K-0.62%Trim
Mar 1, 2025SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL313$7.48$393.7M-45.73%+35.89%$2.3K-0.27%Trim
Feb 28, 2025SellEBSPaul Anthony WilliamsSVP, Products Business498$7.48$393.7M-45.73%+35.89%$3.7K-1.03%Trim
Feb 28, 2025SellEBSRichard S LindahlEVP, Chief Financial Officer1,756$7.48$393.7M-45.73%+35.89%$13.1K-0.57%Trim
Feb 9, 2025SellEBSJessica PerlSVP, General Counsel, Corp Sec918$10.00$393.7M-45.73%+35.89%$9.2K-13.49%Trim
Dec 8, 2024SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL18,674$9.01$393.7M-45.73%+35.89%$168.3K-11.45%Trim
Nov 11, 2024SellEBSWilliam HartzelSVP, Bioservices632$11.97$393.7M-45.73%+35.89%$7.6K-1.31%Trim
Jul 8, 2024SellEBSPaul Anthony WilliamsSVP, Products Business85$8.13$393.7M-45.73%+35.89%$691.05-0.35%Trim
Jun 8, 2024SellEBSPaul Anthony WilliamsSVP, Products Business464$6.19$393.7M-45.73%+35.89%$2.9K-1.86%Trim
Jun 8, 2024SellEBSWilliam HartzelSVP, Bioservices1,167$6.19$393.7M-45.73%+35.89%$7.2K-3.40%Trim
Jun 8, 2024SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL1,249$6.19$393.7M-45.73%+35.89%$7.7K-0.76%Trim
Jun 8, 2024SellEBSJennifer Lynne FoxEVP, Ext Aff, GC, Corp Sec2,376$6.19$393.7M-45.73%+35.89%$14.7K-1.37%Trim
Jun 8, 2024SellEBSRichard S LindahlEVP, Chief Financial Officer2,733$6.19$393.7M-45.73%+35.89%$16.9K-1.72%Trim
Apr 7, 2024SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL585$2.29$393.7M-45.73%+35.89%$1.3K-0.35%Trim
Apr 7, 2024SellEBSWilliam HartzelSVP, Bioservices665$2.29$393.7M-45.73%+35.89%$1.5K-1.90%Trim
Mar 5, 2024SellEBSWilliam HartzelSVP, Bioservices346$3.41$393.7M-45.73%+35.89%$1.2K-0.98%Trim
Mar 1, 2024SellEBSColeen GlessnerEVP, Quality & Ethics, and CPL381$3.39$393.7M-45.73%+35.89%$1.3K-0.23%Trim
Feb 29, 2024SellEBSPaul Anthony WilliamsSVP, Products Business587$3.27$393.7M-45.73%+35.89%$1.9K-1.16%Trim
Feb 29, 2024SellEBSJennifer Lynne FoxEVP, Ext Aff, GC, Corp Sec4,806$3.25$393.7M-45.73%+35.89%$15.6K-1.36%Trim
Feb 29, 2024SellEBSRichard S LindahlEVP, Chief Financial Officer9,721$3.24$393.7M-45.73%+35.89%$31.5K-2.96%Trim
Feb 23, 2024SellEBSPaul Anthony WilliamsSVP, Products Business105$2.74$393.7M-45.73%+35.89%$287.7-0.41%Trim
Feb 23, 2024SellEBSJennifer Lynne FoxEVP, Ext Aff, GC, Corp Sec229$2.74$393.7M-45.73%+35.89%$627.46-0.13%Trim
Feb 23, 2024SellEBSRichard S LindahlEVP, Chief Financial Officer517$2.74$393.7M-45.73%+35.89%$1.4K-0.31%Trim
Nov 13, 2023SellEBSPaul Anthony WilliamsSVP, Products Business566$1.82$393.7M-45.73%+35.89%$1.0K-2.17%Trim
Nov 11, 2023SellEBSJennifer Lynne FoxEVP, Ext Aff, GC, Corp Sec413$2.00$393.7M-45.73%+35.89%$826-0.23%Trim
Nov 11, 2023SellEBSWilliam HartzelSVP, Bioservices632$2.00$393.7M-45.73%+35.89%$1.3K-1.76%Trim